WuXi PharmaTech

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015 01:50 PM

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

More... »

Quest Diagnostics

WuXi PharmaTech forms special committee to evaluate non-binding proposal

Friday, May 15, 2015 02:22 PM

Global CRO WuXi PharmaTech has announced that, in response to a preliminary non-binding proposal letter, dated April 29, received by the company's board of directors from Dr. Ge Li, founder, chairman and CEO of the company, and Ally Bridge Group Capital Partners to acquire the company in a "going private" transaction, the board has formed a special committee of independent directors consisting of Xuesong (Jeff) Leng, William R. Keller and Walter T. Kwauk to evaluate the proposed transaction.  

More... »


WuXi NextCODE Genomics, DNAnexus partner

Friday, April 24, 2015 01:27 PM

WuXi NextCODE Genomics, a subsidiary of WuXi PharmaTech, an open-access R&D capability and technology platform company, and DNAnexus, an cloud-based genome informatics and data management company, have formed a strategic alliance that aims to accelerate the use of genomics to benefit patients worldwide.

More... »

WuXi PharmaTech acquires NextCODE Health

Friday, January 9, 2015 01:58 PM

WuXi PharmaTech, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries with operations in China and the U.S., has acquired NextCODE Health, a genomic analysis and bioinformatics company with operations in the U.S. and Iceland, for $65 million in cash.

More... »

WuXi opening offices in Boston and San Francisco

Monday, December 22, 2014 02:13 PM

CRO WuXi PharmaTech (Cayman), an open-access R&D capability and technology platform company with operations in China and the U.S., will open offices in Boston and San Francisco in early 2015.

More... »

WuXi AppTec launches enhanced genomics services for Chinese researchers

Monday, December 1, 2014 12:39 PM

WuXi PharmaTech, an open-access R&D capability and technology platform company serving the pharma, biotech and medical device industries with operations in China and the U.S., has announced an enhancement to its genomics services. The WuXi Genome Center will provide Chinese researchers who use its gene sequencing services with access to the integrated sequence analysis capabilities of NextCODE Health, a bioinformatics company based in Cambridge, Mass.

More... »

WuXi PharmaTech acquires XenoBiotic Laboratories

Wednesday, October 1, 2014 01:11 PM

CRO WuXi PharmaTech, with operations in China and the U.S., has acquired XenoBiotic Laboratories (XBL), a CRO with facilities in New Jersey and China. Financial terms have not been disclosed.

More... »

FDA approves WuXi’s manufacture of ibalizumab in China for use under a U.S. IND

Wednesday, May 7, 2014 01:32 PM

The FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product, manufactured at WuXi PharmaTech's biologics facilities and developed by TaiMed Biologics for the treatment of HIV/AIDS infection. 

More... »

WuXi PharmaTech invests in TruTag security platform for drug safety

Monday, April 7, 2014 12:36 PM

CRO WuXi PharmaTech, with operations in China and the U.S., and TruTag Technologies, developer of an edible, covert security platform to address the global product counterfeiting challenge, have announced that WuXi Corporate Venture Fund has made an investment in TruTag.

More... »

WuXi PharmaTech, Pharmacyclics to partner

Monday, November 18, 2013 01:48 PM

CRO WuXi PharmaTech, with operations in China and the U.S., said its subsidiary Shanghai SynTheAll (STA) Pharmaceutical has entered into a supply arrangement with Pharmacyclics. This follows a successful multiple-year development and clinical manufacturing partnership that supported Pharmacyclics with an expedited NDA submission and final approval by the FDA of Imbruvica  on Nov. 13, for treatment of patients with mantle cell lymphoma who have received at least one prior therapy.  This indication is based on overall response rate. An improvement in survival or disease-related symptoms has not been established. 

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs